on Zomedica Corp. (NASDAQ:ZOM)
Noble Capital Markets Initiates Coverage on Zomedica
Zomedica Corp., a veterinary health company, announced that Noble Capital Markets has begun equity research coverage on the company. This development could bring increased visibility to Zomedica's financial health and market potential, as the detailed report is now accessible through Channelchek.
Known for their therapeutic and diagnostic solutions for animals, Zomedica's notable products include the PulseVet shock wave system and the TRUFORMA diagnostic platform. With a strong presence in the U.S. market valued at over $2 billion, the company reported a 33% revenue increase in 2023, reaching $25 million.
Zomedica’s strategic focus includes expanding its product offerings and international presence. With $78 million in liquidity as of September 2024, the company aims to enhance veterinary practice profitability and care quality for pets.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news